Valerio MR, Arrivas Bajardi E, Arcara CC, Borsellino N, et al. Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety. Am J Clin Oncol 2021 Jan 20. pii: 00000421-900000000-98598.
PMID: 33481372